Latest filing published 19 Mar 2021 for Avid Bioservices, Inc., €1.5M.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Mark R. Bamforth: trading record in brief
Mark R. Bamforth has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Avid Bioservices, Inc. and Genzyme Corp. In total, 21 filings cover trades dated from 15 July 2008 to 17 March 2021.
Both buying and selling appear: 12 purchases worth €2.3M, against 4 sales worth €3.3M. Sales outweigh purchases by €984k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant and 4 option exercises. In 2021 alone, the filings show 1 purchase and 2 sales.
In size, the median ticket on the buying side is €20k. Clusters matter here: 2 out of 10 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 19 March 2021 with an open-market sale (€397k) in Avid Bioservices, Inc. The clock since the last published purchase (19 March 2021) now reads 2,061 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Mark R. Bamforth
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 100,000 shares@ US$18.1836.1% of flowCommon Stock, $0.001 par valueSEC:0001683168-21-001011:0
- 26,000 shares@ US$18.189.4% of flowCommon Stock, $0.001 par valueSEC:0001683168-21-001011:1
- 126,000 shares@ US$18.1845.5% of flowCommon Stock, $0.001 par valueSEC:0001683168-21-001011:2Canonical exit: 15 Jun 2021 (T+90)
- 26,000 shares@ US$4.01100.0% of flowCommon Stock, $0.001 par valueSEC:0001683168-20-000827:0Canonical exit: 11 Jun 2020 (T+90)
- 50,000 shares@ US$2.2523.9% of flowCommon Stock, $0.001 par valueSEC:0001683168-18-000476:0Canonical exit: 16 May 2018 (T+90)
- 200 shares@ US$4.480.2% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:0Canonical exit: 25 Jan 2018 (T+90)
- 4,993 shares@ US$4.495.1% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:1Canonical exit: 25 Jan 2018 (T+90)
- 1,800 shares@ US$4.491.8% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:2Canonical exit: 25 Jan 2018 (T+90)
- 300 shares@ US$4.490.3% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:3Canonical exit: 25 Jan 2018 (T+90)
- 201 shares@ US$4.490.2% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:4Canonical exit: 25 Jan 2018 (T+90)
- 5,340 shares@ US$4.495.5% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:5Canonical exit: 25 Jan 2018 (T+90)
- 35,966 shares@ US$4.5137.0% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:6Canonical exit: 25 Jan 2018 (T+90)
- 1,200 shares@ US$4.511.2% of flowCommon Stock, $0.001 par valueSEC:0001683168-17-002766:7Canonical exit: 25 Jan 2018 (T+90)
- 700 shares@ US$54.54Genzyme common stock (GENZ)SEC:0000732485-09-000009:0Canonical exit: 2 Jun 2009 (T+90)
- 19,200 shares@ US$43.90Genzyme common stock (GENZ)SEC:0000732485-08-000027:0
- 32 shares@ US$41.50Genzyme common stock (GENZ)SEC:0000732485-08-000027:1
- 19,232 shares@ US$81.71Genzyme common stock (GENZ)SEC:0000732485-08-000027:2
- 6,445 shares@ US$32.52Genzyme common stock (GENZ)SEC:0000732485-08-000024:0
- 6,445 shares@ US$79.00Genzyme common stock (GENZ)SEC:0000732485-08-000024:1
- 6,445 shares0Genzyme common stock (GENZ)SEC:0000732485-08-000019:0
- 6,445 shares@ US$79.00Genzyme common stock (GENZ)SEC:0000732485-08-000019:1
21 of 21 declarations
